City page
Photo: Flocci Nivis · CC BY 4.0Berlin biotech and pharma directory
Berlin’s life-science base combines research, clinical translation, and commercial operators. The Max Delbrück Center works from Berlin-Buch and Berlin-Mitte on systems medicine and cardiovascular disease, in partnership with Charité and the Berlin Institute of Health. Charité’s research spans basic and patient-oriented medicine, while HealthCapital Berlin-Brandenburg coordinates regional networking and technology transfer. The directory includes pharmaceutical, biotech, diagnostics, and digital-health profiles, but their actual laboratory, headquarters, and production locations should be checked individually.
Where does this city read strongest?
Therapeutics (3), Research (2), and Cluster (1). Most visible records: JPT Peptide Technologies, 3B Pharmaceuticals, and TissUse.
Which standards and public evidence are already visible?
GMP (2), GLP (1), and ISO-13485 (1). Latest review: 22 March 2026. Review cycle: March 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Berlin.
Local sources
Primary sources for the local ecosystem
These links let you verify this page’s local context with the primary institution.
Max Delbrück Center
The Helmholtz research centre’s facts and locations for its work in systems medicine and cardiovascular disease.
Open sourceCharité research
Charité’s overview of its basic, clinical, and patient-oriented medical research.
Open sourceHealthCapital Berlin-Brandenburg
The regional healthcare cluster’s information on life-science networking, technology transfer, and market entry support.
Open sourceBy category
Berlin by category
Jump into a category page filtered to this country only.
Full list
Berlin biotech and pharma directory
9 city records currently match the active filter.
Current review cycle
JPT Peptide Technologies
BerlinGermanyTools
Berlin peptide-technology company producing research, assay, and clinical-grade peptide products for immunology, oncology, and biomarker workflows.
- Lead
- Aurelien ClaeyssenManaging Director
- Scale
- Global peptide products platform
Current review cycle
3B Pharmaceuticals
BerlinGermanyTherapeutics
Berlin radiopharmaceutical company developing peptide-targeted cancer therapeutics and companion diagnostics from a German translational-oncology base.
- Lead
- Ulrich HaagmannChief Executive Officer
- Scale
- Development-stage radiopharma platform
Current review cycle
TissUse
BerlinGermanyResearch
Berlin organ-on-chip company developing multi-organ microphysiological systems for drug development, toxicology, and advanced human tissue models.
- Lead
- Uwe MarxChief Executive Officer
- Scale
- Research-platform operations
Current review cycle
T-Knife
BerlinGermanyTherapeutics
Berlin T-cell therapy company building TCR-engineered cell therapies for solid tumors from a German oncology platform.
- Lead
- Gabriele EisnerChief Executive Officer
- Scale
- Clinical-stage cell-therapy platform
Current review cycle
ProBioGen
BerlinGermanyCDMO
Berlin CDMO and biologics technology company providing cell-line development, process development, and GMP manufacturing services for complex biopharmaceuticals.
- Lead
- Volker SandigChief Executive Officer and Chief Scientific Officer
- Scale
- Commercial and clinical biopharma platform
Current review cycle
Campus Berlin-Buch
BerlinGermanyCluster
Berlin-Buch science and biotech campus integrating research institutes, translational platforms, spinouts, and grow-out infrastructure for biomedical companies.
- Lead
- Dr. Christina Quensel / Dr. Ulrich SchellerManaging Directors
- Scale
- Berlin-Buch biotech campus operations
Current review cycle
Eckert & Ziegler
BerlinGermanyManufacturing
Berlin radiopharma and isotope-products anchor spanning medical isotopes, radiation components, and nuclear-medicine supply.
- Lead
- Dr. Harald HasselmannChief Executive Officer
- Scale
- International isotope and radiopharma platform
Current review cycle
Max Delbruck Center Berlin-Buch
BerlinGermanyResearch
Berlin-Buch biomedical research centre combining disease-biology programmes, technology platforms, and translational partnerships across the German capital region.
- Lead
- Prof. Dr. Maike SanderChair of the Board and Scientific Director
- Scale
- Large biomedical research centre
Current review cycle
Apogenix AG
BerlinGermanyTherapeutics
Heidelberg immunotherapy developer focused on TNFSF pathway biology and clinical-stage oncology programs built from its asunercept platform.
- Lead
- Dr. Thomas HoegerChief Executive Officer
- Scale
- Clinical Research
FAQ
Frequently asked questions
- What biotech companies are headquartered in Berlin?
- Use the current directory list below for companies with Berlin records. It includes pharmaceutical, biotech, diagnostics, and digital-health organisations. The surrounding Berlin-Brandenburg region is broader than the city, so open every profile to confirm its documented address and operating role before drawing a commercial conclusion.
- What research institutions anchor Berlin biotech?
- The Max Delbrück Center is a Helmholtz research centre with sites in Berlin-Buch and Berlin-Mitte, and it works with Charité and the Berlin Institute of Health on translational research. Charité supports basic, clinical, and patient-oriented research. Their partnership is a useful research signal, but it does not substitute for evidence about an individual company or facility.
- How does Berlin compare to Heidelberg or Munich for biotech?
- Berlin is useful when you need a large metropolitan mix of biomedical research, clinical research, pharma, diagnostics, and digital health. Heidelberg and Munich have different local research and company profiles. Compare the actual categories, evidence, and site types in each directory page instead of relying on a single regional ranking.
Related briefs
Briefs that mention Berlin
European Viral Vector CDMO Guide 2026: AAV, Adenovirus, Lentivirus
A source-backed guide to publicly stated European viral-vector CDMO capabilities in 2026: AAV, adenovirus, lentivirus, pDNA, and the questions to ask before a manufacturing enquiry.
Open briefGerman Biotech & Pharma Landscape 2026: Heidelberg, Berlin, Mainz
A practical map of the German biotech and pharma landscape in 2026 - 57 operators across Heidelberg, Berlin, Mainz, Hamburg, Munich, and smaller sites, organised by what they actually do and how the pieces connect.
Open briefCell & Gene Therapy Europe 2026: CAR-T, Stem Cell, ATMP, Regenerative
A practical map of the European cell and gene therapy landscape in 2026 - CAR-T and TCR-T therapeutics, stem-cell and regenerative ATMPs, tissue engineering, plus the viral-vector CDMO and tools supply chain - across 26 operators in the directory.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.